{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:09Z","timestamp":1793949549807,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2242,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA003889"],"award-info":[{"award-number":["R01DA003889"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s13311-017-0542-y","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T10:35:09Z","timestamp":1496658909000},"page":"734-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":263,"title":["Potential Therapeutic Effects of Psilocybin"],"prefix":"10.1016","volume":"14","author":[{"given":"Matthew W.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-017-0542-y_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.163.3864.245","article-title":"Hallucinogens of plant origin","volume":"163","author":"Schultes","year":"1969","journal-title":"Science"},{"key":"10.1007\/s13311-017-0542-y_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/00275514.1971.12019194","article-title":"New records of mushroom stones from Guatemala","volume":"63","author":"Lowy","year":"1971","journal-title":"Mycologia"},{"key":"10.1007\/s13311-017-0542-y_bib3","series-title":"Plants of the gods: their sacred, healing, and hallucinogenic powers","author":"Schultes","year":"1992"},{"key":"10.1007\/s13311-017-0542-y_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01825267","article-title":"Ueber Pellote. Beitrag zur chemischen und pharmakologischen Kenntnis der Cacteen","volume":"40","author":"Heffter","year":"1898","journal-title":"Naunyn-Schmiedebergs Arch Exp Pathol Pharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib5","first-page":"6","article-title":"Visions of the Night: Western medicine meets peyote 1887-1899","volume":"2","author":"Perrine","year":"2001","journal-title":"Heffter Rev Psychedel Res"},{"key":"10.1007\/s13311-017-0542-y_bib6","series-title":"LSD, my problem child","author":"Hofmann","year":"1980"},{"key":"10.1007\/s13311-017-0542-y_bib7","series-title":"Psychedelic drugs reconsidered","author":"Grinspoon","year":"1979"},{"key":"10.1007\/s13311-017-0542-y_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/j.2326-1951.1981.tb01901.x","volume":"21","author":"Grinspoon","year":"1981","journal-title":"LSD Reconsidered. Sciences"},{"key":"10.1007\/s13311-017-0542-y_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesth Analg"},{"key":"10.1007\/s13311-017-0542-y_bib10","first-page":"69","article-title":"LSD and the Anguish of Dying","volume":"231","author":"Cohen","year":"1965","journal-title":"Harpers Magazine"},{"key":"10.1007\/s13311-017-0542-y_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatr Q"},{"key":"10.1007\/s13311-017-0542-y_bib12","series-title":"The Present Status of Psychotropic Drugs: Pharmacological and Clinical Aspects","first-page":"432","article-title":"Psychedelic psychotherapy (LSD) in the treatment of the patient with a malignancy","author":"Kurland","year":"1969"},{"key":"10.1007\/s13311-017-0542-y_bib13","first-page":"144","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Curr Psychiatr Ther"},{"key":"10.1007\/s13311-017-0542-y_bib14","first-page":"121","article-title":"LSD-assisted psychotherapy and the human encounter with death","volume":"4","author":"Richards","year":"1972","journal-title":"J Transpers Psychol"},{"key":"10.1007\/s13311-017-0542-y_bib15","series-title":"Patients With Terminal Cancer Psychotheramacological Agents for the Terminally Ill and Bereaved","first-page":"86","article-title":"Psychedelic drug assisted psychotherapy","author":"Kurland","year":"1973"},{"key":"10.1007\/s13311-017-0542-y_bib16","series-title":"The Human Encounter with Death","author":"Halifax","year":"1977"},{"key":"10.1007\/s13311-017-0542-y_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1977.10472020","article-title":"The peak experience variable in DPT-assisted psychotherapy with cancer patients","volume":"9","author":"Richards","year":"1977","journal-title":"J Psychedel Drugs"},{"key":"10.1007\/s13311-017-0542-y_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2190\/NGUB-V4RM-T7DC-XTH3","article-title":"DPT as an adjunct in brief psychotherapy with cancer patients","volume":"10","author":"Richards","year":"1980","journal-title":"OMEGA J Death Dying"},{"key":"10.1007\/s13311-017-0542-y_bib19","series-title":"LSD Psychotherapy","author":"Grof","year":"1980"},{"key":"10.1007\/s13311-017-0542-y_bib20","first-page":"309","article-title":"Psychedelic drug-assisted psychotherapy with persons suffering from terminal cancer","volume":"5","author":"Richards","year":"1979","journal-title":"J Altered States Consciousness"},{"key":"10.1007\/s13311-017-0542-y_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/02791072.1985.10524332","article-title":"LSD in the supportive care of the terminally ill cancer patient","volume":"17","author":"Kurland","year":"1985","journal-title":"J Psychoactive Drugs"},{"key":"10.1007\/s13311-017-0542-y_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","article-title":"Use of d-lysergic acid diethylamide in the treatment of alcoholism","volume":"20","author":"Chwelos","year":"1959","journal-title":"Q J Stud Alcohol"},{"key":"10.1007\/s13311-017-0542-y_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism: I. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q J Stud Alcohol"},{"key":"10.1007\/s13311-017-0542-y_bib24","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am J Psychiatry."},{"key":"10.1007\/s13311-017-0542-y_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0028-1094301","article-title":"LSD in the treatment of alcoholics","volume":"4","author":"Kurland","year":"1971","journal-title":"Pharmacopsychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q J Stud Alcohol"},{"key":"10.1007\/s13311-017-0542-y_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J Nerv Mental Dis"},{"key":"10.1007\/s13311-017-0542-y_bib30","series-title":"Psilocybin mushrooms of the world","author":"Stamets","year":"1996"},{"key":"10.1007\/s13311-017-0542-y_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1007\/s13311-017-0542-y_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.pbb.2007.06.003","article-title":"Psilocybin-induced stimulus control in the rat","volume":"87","author":"Winter","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-017-0542-y_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"key":"10.1007\/s13311-017-0542-y_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav Pharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-017-0542-y_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers","volume":"123","author":"Johnson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-017-0542-y_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1007\/s13311-017-0542-y_bib42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting highs at rock bottom': LSD treatment for alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc Hist Med"},{"key":"10.1007\/s13311-017-0542-y_bib44","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","article-title":"Assessment of addiction severity among ritual users of ayahuasca","volume":"111","author":"Fabregas","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-017-0542-y_bib46","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1176\/ajp.131.11.1247","article-title":"Peyote in the treatment of alcoholism among American Indians","volume":"131","author":"Albaugh","year":"1974","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/ajp.128.6.695","article-title":"Navajo peyote use: its apparent safety","volume":"128","author":"Bergman","year":"1971","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/15563657708988210","article-title":"Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale","volume":"11","author":"Blum","year":"1977","journal-title":"Clin Toxicol"},{"key":"10.1007\/s13311-017-0542-y_bib49","first-page":"237","article-title":"Spiritual healing and human development in the Native American church: toward a cultural psychiatry of peyote","volume":"84","author":"Calabrese","year":"1997","journal-title":"Psychoanal Rev"},{"key":"10.1007\/s13311-017-0542-y_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/02791072.2002.10399960","article-title":"Hallucinogens and redemption","volume":"34","author":"de Rios","year":"2002","journal-title":"J Psychoactive Drugs"},{"key":"10.1007\/s13311-017-0542-y_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1525\/maq.2000.14.4.521","article-title":"Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing","volume":"14","author":"Garrity","year":"2000","journal-title":"Med Anthropol Q"},{"key":"10.1007\/s13311-017-0542-y_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/16066359609010756","article-title":"The use of hallucinogens in the treatment of addiction","volume":"4","author":"Halpern","year":"1996","journal-title":"Addict Res"},{"key":"10.1007\/s13311-017-0542-y_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/02791072.1976.10472016","article-title":"Ethnopsychedelic therapy for alcoholics: observations in the peyote ritual of the Native American Church","volume":"8","author":"Pascarosa","year":"1976","journal-title":"J Psychedelic Drugs"},{"key":"10.1007\/s13311-017-0542-y_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/15313204.2013.843138","article-title":"Indigenous supports for recovery from alcoholism and drug abuse: the Native American Church","volume":"22","author":"Prue","year":"2013","journal-title":"J Ethn Cult Divers Soc Work"},{"key":"10.1007\/s13311-017-0542-y_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1176\/ajp.130.3.329-b","article-title":"Indian peyotists and alcohol","volume":"130","author":"Roy","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1007\/s13311-017-0542-y_bib57","series-title":"Distilled Spirits: Getting High, then Sober, with a Famous Writer, a Forgotten Philosopher, and a Hopeless Drunk","author":"Lattin","year":"2012"},{"key":"10.1007\/s13311-017-0542-y_bib58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1007\/s13311-017-0542-y_bib60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1007\/s13311-017-0542-y_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","author":"Johnson","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0542-y_bib63","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-017-0542-y_bib64","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0542-y_bib65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J Psychoact Drugs"},{"key":"10.1007\/s13311-017-0542-y_bib66","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-017-0542-y_bib67","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-017-0542-y_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0542-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:03:07Z","timestamp":1761807787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1878747923014514"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0542-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Therapeutic Effects of Psilocybin","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0542-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}